According to our new research study on "Patient-Derived Xenograft Model Market Forecast to 2031 - Global Analysis - by Type, Tumor Type, Application, End User, and Geography," the market is expected to grow from US$ 468.75 million in 2024 to US$ 1,119.36 million by 2031; it is estimated to record a CAGR of 13.5% from 2025-2031. Key factors driving the growth of the patient-derived xenograft model market are the rising prevalence of cancer and the growing demand for personalized medicine.

The scope of the patient-derived xenograft model market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. Asia Pacific is anticipated to register the fastest CAGR in the patient-derived xenograft model market from 2025 to 2031. The escalating cancer rate in countries like China, Japan, India, and South Korea is the main reason behind the demand for highly predictive and personalized preclinical models in oncology research. The trend of using PDX models for drug discovery and development has been further boosted by the significant investments in biomedical research and the rapid growth of the pharmaceutical and biotechnology industries, thereby supporting the patient-derived xenograft model market growth in the Asia Pacific. Regional governments are fueling the cancer fight by providing funds through different initiatives, collaborations, and regulatory reforms that pave the way for translational medicine, accelerating the growth of the Asia-Pacific patient-derived xenograft model market in the near future. Besides that, a genetically diverse patient population in the Asia-Pacific can help researchers get more accurate cancer models in the region, speeding up drug efficacy testing and the development of personalized therapy, thus becoming a significant factor aiding the patient-derived xenograft model market in the region. The increasing number of CROs that provide cost-effective PDX services and the rapid progress in molecular profiling, genomics, and animal modeling technologies are some of the other factors that are driving the market growth.

Furthermore, PDX models have been utilized to study multiple myeloma by implanting tumor cells of Chinese patients, thus allowing the evaluation of drug efficacy in a local genetic background, and in hepatocellular carcinoma via novel co-culturing methods that open new paths for model fidelity. These models go beyond the gap between lab results and patient outcomes; thus, they are the main tools for process validation in biopharmaceutical production and the major source of the breakthrough wave in academic and contract research settings, further fueling the growth of the patient-derived xenograft model market.

The most recent 2024-2025 developments are marked by substantial advances, for instance, the establishment of a complete Chinese PDX library for gastrointestinal cancers with an emphasis on ESCC, which serves as a resource for detailed tumor analysis. Early 2025 saw progress in personalized drug screening by integrating PDX with genomic sequencing, primarily focusing on tumor target discovery and resistance mechanisms, while a review of liver cancer PDX models spoke of better preparation for clinical translation. Model deployment has become more efficient due to regulatory approvals and collaborations such as the one involving Crown Biosciences expansion in 2023, which has become more attractive to Thermo Fisher oncology investments and Jinshan immuno-oncology partnership.

Additionally, the patient-derived xenograft model market is accelerating with the increasing cases of gastric cancer in Japan, about 130,000 times a year, whereas the death rate from colorectal cancer is expected to increase by 15% in the next twenty years, which will be the main reason for the increased use of PDX for metastasis modeling and therapy evaluation. There are numerous examples in Japan research of such models, like stomach cancer PDX models that originated from the comparison of primary tumor pathology with cell-line derived xenografts to maintain heterogeneity and stromal components, bolstering the patient-derived xenograft model market growth. The PDX models have been identified as a source of preclinical testing for epithelial ovarian cancer, with the success rates being used as a proxy for patient survival outcomes. Therefore, the factors mentioned above are promoting a favorable environment for the patient-derived xenograft model market in the region.

Noble Life Sciences, Charles River Laboratories International Inc, Crown Bioscience Inc, Experimental Pharmacology & Oncology Berlin-Buch GmbH, Hera BioLabs, Oncodesign Services, WuXi AppTec Co. Ltd., BioDuro LLC, XenTech SAS, and Shanghai LIDE Biotech. Co. Ltd. are among the leading companies profiled in the patient-derived xenograft model market report.

Based on type, the patient-derived xenograft model market is bifurcated into rats model and mice model. Based on tumor type, the market is classified into gastrointestinal tumor model, gynecological tumor model, respiratory tumor model, and other tumor models. By application, the market is segmented into preclinical drug development, biomarker analysis, translational research, and biobanking. In terms of end user, the market is classified into pharmaceutical and biotechnology companies, academics and research institutes, and contract research organizations. Geographically, the patient-derived xenograft model market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com